<?xml version='1.0' encoding='utf-8'?>
<document id="27876352"><sentence text="Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound." /><sentence text="The purpose of the present study is to demonstrate a useful approach (isotope-IV method) for analyzing drug-drug interactions (DDIs) following the oral administration of drugs using stable isotope-labeled compounds" /><sentence text=" Verapamil hydrochloride (VER) was used as a drug model"><entity charOffset="1-24" id="DDI-PubMed.27876352.s3.e0" text="Verapamil hydrochloride" /><entity charOffset="26-29" id="DDI-PubMed.27876352.s3.e1" text="VER" /><pair ddi="false" e1="DDI-PubMed.27876352.s3.e0" e2="DDI-PubMed.27876352.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27876352.s3.e0" e2="DDI-PubMed.27876352.s3.e1" /></sentence><sentence text=" Deuterium-labeled VER (VER-d6, 0"><entity charOffset="1-10" id="DDI-PubMed.27876352.s4.e0" text="Deuterium" /><entity charOffset="19-27" id="DDI-PubMed.27876352.s4.e1" text="VER" /><entity charOffset="24-32" id="DDI-PubMed.27876352.s4.e2" text="VER" /><pair ddi="false" e1="DDI-PubMed.27876352.s4.e0" e2="DDI-PubMed.27876352.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27876352.s4.e0" e2="DDI-PubMed.27876352.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27876352.s4.e0" e2="DDI-PubMed.27876352.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27876352.s4.e1" e2="DDI-PubMed.27876352.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27876352.s4.e1" e2="DDI-PubMed.27876352.s4.e2" /></sentence><sentence text="005 mg/kg) was intravenously administered to rats with or without a pre-treatment with 1-aminobenzotriazole (ABT, 100 mg/kg), a potent CYP inhibitor, 1"><entity charOffset="87-107" id="DDI-PubMed.27876352.s5.e0" text="1-aminobenzotriazole" /><entity charOffset="109-112" id="DDI-PubMed.27876352.s5.e1" text="ABT" /><pair ddi="false" e1="DDI-PubMed.27876352.s5.e0" e2="DDI-PubMed.27876352.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27876352.s5.e0" e2="DDI-PubMed.27876352.s5.e1" /></sentence><sentence text="5 h after the oral administration of VER (1 mg/kg)"><entity charOffset="37-39" id="DDI-PubMed.27876352.s6.e0" text="VER" /></sentence><sentence text=" PK parameters such as AUCpo, AUCiv, and CLtot were evaluated after the oral and intravenous administration of VER from the plasma concentration-time profiles of VER and VER-d6 in each rat"><entity charOffset="111-113" id="DDI-PubMed.27876352.s7.e0" text="VER" /><entity charOffset="162-164" id="DDI-PubMed.27876352.s7.e1" text="VER" /><entity charOffset="170-172" id="DDI-PubMed.27876352.s7.e2" text="VER" /><pair ddi="false" e1="DDI-PubMed.27876352.s7.e0" e2="DDI-PubMed.27876352.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27876352.s7.e0" e2="DDI-PubMed.27876352.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27876352.s7.e0" e2="DDI-PubMed.27876352.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27876352.s7.e1" e2="DDI-PubMed.27876352.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27876352.s7.e1" e2="DDI-PubMed.27876352.s7.e2" /></sentence><sentence text=" The oral bioavailability (F) of VER in rats was calculated as 0"><entity charOffset="33-35" id="DDI-PubMed.27876352.s8.e0" text="VER" /></sentence><sentence text="02 ± 0" /><sentence text="01 and was significantly increased to 0" /><sentence text="45 ± 0" /><sentence text="24 by the pre-treatment with ABT"><entity charOffset="29-31" id="DDI-PubMed.27876352.s12.e0" text="ABT" /></sentence><sentence text=" Further PK analyses revealed that CYP-mediated metabolism was more strongly inhibited by ABT in the intestine (Fg) than in the liver (Fh)"><entity charOffset="90-92" id="DDI-PubMed.27876352.s13.e0" text="ABT" /></sentence><sentence text=" These results were consistent with those obtained using the conventional method in which oral and intravenous administration studies were performed using different rat groups" /><sentence text=" Therefore, the isotope-IV method is effective for performing PK analyses including DDIs after the oral administration of drugs" /><sentence text="" /></document>